As a new-type foreign trade service provider driven by both technology transformation and foreign trade business, HiSiaddi has established a "1+2+3+4=1" service system and can supply original factory sources of Tris(dibenzylideneacetone)dipalladium chloroform adduct from multiple well-known brands.
With R&D capabilities, HiSiaddi has conducted multiple rounds of on-site inspections of manufacturers producing Tris(dibenzylideneacetone)dipalladium chloroform adduct through technological transformation cooperation with manufacturers, maintaining objective and in-depth understanding of different brands. We regularly analyze manufacturers of Tris(dibenzylideneacetone)dipalladium chloroform adduct for clients to help them select suitable products. Below is a brand recommendation case.
For more brand and model comparison analysis, please contact HiSiaddi customer service.
Synthea AG, a Zurich-based Swiss high-end innovative drug CDMO, specializes in commercial mass production of small-molecule targeted APIs and pre-clinical new drug process development. The company regularly purchases original Tris(dibenzylideneacetone)dipalladium chloroform adduct from Johnson Matthey and Merck with an annual demand of 120 kg for industrialized Buchwald-Hartwig and Suzuki coupling reactions, classifying it as a mid-to-high-end pharmaceutical purchaser. Mandatory product specifications align with EP Pharmacopoeia, with strict control over four core parameters: palladium content, free DBA, solvent residues and powder particle size.
Faced with surging European precious metal prices and extended overseas manufacturer delivery lead times of up to 70 days, the client planned localized substitution and independently requested samples and quotations from five domestic manufacturers (Wuhan LPB Phosphine & Palladium, Jiangsu Beida, Wuhan Jiaderuifeng, Beijing J&K Scientific, Shandong Gongchuang). A widespread industry issue emerged: sales representatives of each manufacturer prioritized promoting their full product lines, emphasizing their own advantages while avoiding objective disclosure of competing brands’ applicable strengths, weaknesses and working condition compatibility. After receiving samples of five different specifications, laboratory small-batch test data varied drastically, with some grades exhibiting catalytic activity mismatched to the client’s continuous production line, delaying final brand confirmation. The client entrusted HiSiaddi to conduct neutral third-party brand evaluation and horizontal model selection.
HiSiaddi collected full-product COA test reports, samples and factory quality control standards from all five manufacturers, then sorted product lines into three tiers (general industrial grade, pharmaceutical R&D grade, high-end pharmacopoeia grade) aligned with the client’s pharmaceutical coupling process requirements, objectively listing pros and cons of each brand without bias toward any manufacturer:
· Grade ① LPB-PD01 (General Industrial Grade): Palladium content 19.9%–20.6%, free DBA >900 ppm, irregular natural crystallization particle sizes. Suitable for low-end fine chemical intermittent small trials. Advantages: Low unit price, abundant stock; Disadvantages: Excessive impurities, unsuitable for pharmaceutical API mass production.
· Grade ② LPB-PD02 (Standard Pharmaceutical Grade): Palladium content 20.3%±0.2%, free DBA ≤350 ppm. For small-batch production of standard pharmaceutical intermediates with outstanding cost performance.
· Grade ③ LPB-PD03 (High-End Pharmacopoeia Custom Grade): Precise palladium content 20.35%±0.1%, free DBA ≤190 ppm, stable chloroform intercalation, directional crystal control with D50=20–26 μm. Fully compliant with EP Pharmacopoeia, supplied with bilingual COA and REACH documents, matching the quality of original Johnson Matthey products. Disadvantages: Relatively high price, minimum order quantity of 5 kg. Brand strengths: Deep expertise in precious metal catalytic synthesis, customizable formula adjustments; Weaknesses: General grades suffer inconsistent batch stability.
· Grade BD-97 (Mid-Tier Pharmaceutical Grade): 97% purity, palladium content fluctuating by ±0.3%, elevated free solvent residues. Suitable for university laboratory research screening with high risk of activity fluctuations during mass production. Advantages: Sufficient mass production capacity, fast lead times.
· Grade BD-98HP (High-End Refined Grade): Meets impurity control standards but lacks directional particle size regulation technology, yielding uneven coarse and fine powder. Compatible with non-automated intermittent reactor lines, incompatible with the client’s closed continuous feeding equipment. Brand strengths: Low cost via large-scale mass production; Weaknesses: Underdeveloped refined crystallization processes, no high-end narrow particle size distribution grades.
· Grade JDR-STD (Standard Reagent Grade): 98% purity, preferred for small-scale R&D trials with complete small packaging sizes. No mass-production pharmacopoeia-grade specifications; unstable quality control for bulk mass supply, prone to coordination imbalance and palladium black precipitation in large batches. Brand strengths: Cost-effective small samples ranging from 1 g to 500 g; Weaknesses: Unsuitable for industrial continuous production of tens of kilograms.
· Grade JK-R (Imported Repackaged Grade): Repackaged Sigma raw materials with indicators close to imported standards, yet supply is vulnerable to fluctuations in overseas raw material availability with unstable bulk delivery lead times. Unit prices significantly exceed self-produced domestic high-end products, only suitable for sporadic R&D procurement with no advantages for large-volume stock preparation. Brand strengths: Stable individual indicators; Weaknesses: No independent synthetic production lines, uncontrollable mass supply capacity.
Full GC-series industrial-grade products with universal free organic impurities >1000 ppm. Only applicable for crude chemical processing, with no pharmaceutical-compliant grades failing to meet European pharmaceutical enterprise pharmacopoeia access thresholds. Brand strengths: Lowest market price; Weaknesses: Excessive impurities, inadmissible for pharmaceutical production lines.
Core client demands: 120 kg annual mass production, automated closed feeding, EP Pharmacopoeia quality control, stable bulk supply, balanced quality and localized cost reduction. HiSiaddi eliminated three brands unsuitable for the project (Jiaderuifeng, J&K Scientific, Shandong Gongchuang) which only supported small trials, low-end industrial materials or unstable repackaged supply, ultimately selecting Wuhan LPB Phosphine & Palladium and Jiangsu Beida, with three segmented grades for tiered procurement:
1. LPB-PD03 from LPB Phosphine & Palladium (Core High-End Pharmacopoeia Grade, 95 kg annual mass production procurement): Fully compatible with the client’s API continuous production line, meeting all palladium content tolerance, impurity and particle size requirements to replace original Johnson Matthey industrial raw materials, cutting localized procurement unit prices by 31% vs. imported equivalents.
2. LPB-PD02 from LPB Phosphine & Palladium (Standard Pharmaceutical Grade, 15 kg new drug R&D backup material): For small-batch process screening of the client’s new drugs, offering high cost performance for iterative formula testing with small sample quantities.
3. BD-98HP from Jiangsu Beida (Backup Alternative Grade, 10 kg emergency stock): Alternative supply chain to supplement split orders during primary material shortages, leveraging large manufacturer production capacity to mitigate stockout risks.
1. Sample verification phase: HiSiaddi coordinated the two manufacturers to ship three batches of 50 g samples each, accompanied by third-party SGS full-test bilingual reports. Three rounds of small-batch testing at the client’s Zurich laboratory yielded consistent catalytic yields of 94.3%–94.8% for LPB-PD03, matching original Merck performance. The two backup grades satisfied R&D and emergency stock requirements, completely resolving the client’s model selection confusion.
2. First batch order delivery: The initial 40 kg was shipped split across three grades. HiSiaddi uniformly compiled REACH SDS, CLP compliance labels and dangerous goods export documentation, completing one-stop customs declaration and sea freight to Switzerland. No abnormalities arose during full-line production after material arrival, with zero palladium black precipitation and no batch-to-batch catalytic activity fluctuations.
3. Signing of annual framework contract: A 120 kg annual procurement framework was finalized with monthly shipments across six batches. The client later launched an anti-fungal new drug project and continued to adopt products from the two pre-selected brands.
1. Industry Pain Point: Sales teams of domestic catalyst manufacturers prioritize promoting their own products, avoiding objective commentary on competitors’ strengths for commercial interests. Overseas mid-to-high-end pharmaceutical enterprises lack tiered awareness of domestic brands and risk selecting inappropriate grades based solely on manufacturers’ one-sided introductions, incurring production line trial costs and raw material losses.
2. Core Value of HiSiaddi: Acting as a neutral third-party foreign trade service provider, we leverage professional precious metal catalysis expertise to conduct horizontal full-brand evaluations, filtering out marketing bias from manufacturers and tiered model selection based on actual client production scenarios. We simultaneously avoid mass production accidents caused by misapplication of low-end industrial materials and control procurement costs for high-end raw materials, securing long-term repeat orders from European mid-to-high-end pharmaceutical enterprises through objective and professional model selection services.
For more brand and model comparison analysis, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
